Category: Baxano SurgicalSyndicate content

SafeStitch lures Baxano CFO Slattery to be new finance chief

September 25, 2013 by Brad Perriello

SafeStitch Medical lures Joseph Slattery to be its new CFO from Baxano, who names former Talecris Biotherapeutics exec Timothy Shannon as interim replacement.

SafeStitch lures Baxano CFO Slattery to be new finance chief
SafeStitch lures Baxano CFO Slattery to be new finance chief

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Baxano lowers full-year guidance amid widening losses, growing sales

August 14, 2013 by Arezu Sarvestani

Baxano fails to meet Wall Streets expectations during its 2nd quarter of 2013, during which the company reinvented itself as Baxano Surgical.

Baxano reinvents itself amid widening losses, growing sales

Baxano Surgical pays $6M to settle federal healthcare fraud beef

July 8, 2013 by Arezu Sarvestani

Baxano Surgical closes the books, without admitting wrong-doing, on a Justice Dept. investigation over allegations of healthcare fraud.

Baxano logo

Covidien CEO Almeida wants more from emerging markets | Wall Street Beat

June 11, 2013 by Arezu Sarvestani

Covidien's doubling down in emerging markets yet again, looking to invest in Brazil, South Africa and Mexico and other high-growth regions in hopes of hitting $2 billion in emerging market revenue "as soon as possible."

MassDevice.com Wall Street Beat

Medical device giant Covidien is doubling down on emerging markets, expanding an investment program that the company had, at one point, thought would be over by the end of 2013.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

On-Q-ity folds its tents after 3 years, $26M | Wall Street Beat

April 12, 2013 by Brad Perriello

Oncology diagnostics company On-Q-ity folds up its tents after an unsuccessful, 3-year bid to develop personalized cancer diagnostics – and burning through $26 million in venture capital backing.

MassDevice.com Wall Street Beat

On-Q-ity, which raised a $26 million Series A round back in December 2009, quietly folded its tents last year after an unsuccessful bid to develop its technology for personalized cancer detection.

Bruce Booth, a partner at Atlas Ventures, 1 of the VC shops that backed the company (and a member of On-Q-ity's board), detailed the reasons behind the decision this week on his blog, Life Sci VC.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp